“Bimekizumab Versus Secukinumab Continuous Maintenance of Response at Every Visit through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-Hoc Results from the BE RADIANT Phase 3b Trial”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s70, https://doi.org/10.25251/skin.6.supp.70.